NY-ALVAREZ-&-MARSAL
11.1.2024 16:01:30 CET | Business Wire | Press release
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 69 professionals, across Europe and Middle East, India, Latin America, North America, North Asia and Southeast Asia & Australia to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their contributions to our core values of integrity, quality, objectivity, fun, personal reward and inclusive diversity are what make A&M unique. Their commitment to help clients maximize value and drive change amidst ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. They, alongside all A&M professionals, are our greatest strength.”
2024 MANAGING DIRECTOR PROMOTIONS
Europe and Middle East
- Cristiano Battelli, Private Equity Performance Improvement -- Milan
- Paul Culham, Global Transaction Advisory Group -- London
- Louis Darrieus, Global Transaction Advisory Group -- Paris
- Steve Green, Debt Advisory -- London
- Josefine Haensel, Corporate Transformation Services -- Hamburg
- Samih Hajar, Global Transaction Advisory Group -- Paris
- Cheng He, Global Transaction Advisory Group -- London
- Michal Kapela, Global Transaction Advisory Group -- Zurich
- Zeeshan Mansoor, Financial Services Industry -- Amsterdam
- Michael Nizet, Financial & Operational Restructuring -- Amsterdam
- Robert Park, Corporate Transformation Services -- London
- Tom Paterson, Debt Advisory -- London
- Adam Paxton, Insolvency -- London
- Felix Schweigger, Private Equity Performance Improvement -- Munich
- Steve Smith, Tax -- London
- Sebastien Trochet, Digital & Technology Services -- Paris
- Yann Varin, Private Equity Performance Improvement -- Paris
- Nick Walton, Tax -- Manchester
India
- Ashish Doshi, Global Transaction Advisory Group -- Mumbai
- Ram Panda, Business Transformation Services -- Mumbai
Latin America
- Guilherme Almeida, Corporate Transformation -- São Paulo
- Luiz Gronau, Infrastructure & Capital Projects (A&M INFRA) -- São Paulo
- Eduardo Magalhaes, Global Disputes and Investigations -- São Paulo
North America
- Richard Behrens, North American Commercial Restructuring -- Los Angeles
- Brett Bergamo, Energy -- Houston
- Amy Best, Global Disputes and Investigations -- Denver
- Matthew Box, Healthcare -- Washington, D.C.
- Aaron Busse, Corporate Performance Improvement -- Atlanta
- Meghan Cardell, Global Disputes and Investigations -- Washington, D.C.
- Evan Colwell, Global Transaction Advisory Group -- Nashville
- Steve Coverick, North American Commercial Restructuring -- Dallas
- Jorge de Los Reyes, Infrastructure & Capital Projects (A&M INFRA) -- Washington, D.C.
- Beata De Zagon, Global Transaction Advisory Group -- Dallas
- Alex Duff, Private Equity Performance Improvement -- New York
- Ryan Duffy, Global Transaction Advisory Group -- Chicago
- Kyle Foust, Tax -- Chicago
- Max Fulton, Private Equity Performance Improvement -- Denver
- Jen Fults, Tax -- New York
- Jeffrey Gerarde, Tax -- Washington, D.C.
- John Hanson, North American Commercial Restructuring -- Dallas
- Sam Jones, Global Transaction Advisory Group -- Chicago
- Andrew Khoo, North American Commercial Restructuring -- New York
- David Knight, Private Equity Performance Improvement -- Houston
- Daniel LaMantia, Private Equity Performance Improvement -- Dallas
- Erin Leveton, Public Sector Services -- Washington, D.C.
- Allen Mahr, North American Commercial Restructuring -- New York
- Matthew Merhan, Corporate Performance Improvement -- Houston
- Derek Myers, Tax -- Atlanta
- Rich Niemerg, North American Commercial Restructuring -- Chicago
- Alan Pender, Energy -- Dallas
- Rob Reid, Infrastructure & Capital Projects (A&M INFRA) -- Atlanta
- Jeffrey Richman, Corporate Finance -- New York
- Brian Rudelson, Tax -- Houston
- Joan Russo, Healthcare -- Miami
- Paul Saftig, Global Transaction Advisory Group -- Chicago
- John Sawyer, Valuation -- Seattle
- Daniel Schmeltz, Corporate Performance Improvement -- Houston
- Jigar Shah, Corporate Performance Improvement -- Los Angeles
- Michael Shanahan, Global Disputes and Investigations -- Philadelphia
- Jeff Swerdlow, Tax -- Denver
- Andrew Thung, Healthcare -- New York
- Jeremy Tilsner, Global Disputes and Investigations -- New York
- Andrey Ulyanenko, Tax -- Miami
- Aaron Umberger, Public Sector Services -- Washington, D.C.
- Mariya Verbitski, Global Transaction Advisory Group -- San Francisco
North Asia
- Dee Chung, Restructuring & Turnaround -- Seoul
- Carmen Yeung, Restructuring & Turnaround -- Hong Kong SAR
Southeast Asia & Australia
- John Sanger, Performance Improvement -- Perth
- Kaustav Sen, Performance Improvement -- Singapore
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 8,500 people across six continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109034313/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom